세계의 심장 양전자 방출 단층촬영(PET) 스캔 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of cardiology positron emission tomography (PET) scan Market

The global cardiology positron emission tomography (PET) scan market continues to expand as demand for advanced non-invasive cardiac diagnostic tools increases worldwide. According to the latest report, the global cardiology PET scan market size was valued at USD 1.91 billion in 2024, supported by rising cardiac disease prevalence, technological advancements in imaging systems, and greater adoption of precision diagnostics. The market is expected to reach USD 1.97 billion in 2025, reflecting steady growth driven by the rising geriatric population and increasing clinical preference for early and accurate cardiac evaluations. Looking ahead, the market is forecast to grow to USD 2.56 billion by 2032, exhibiting a CAGR of 3.8% from 2025 to 2032.

In 2024, North America dominated the global market with a 55.49% share, fueled by strong healthcare infrastructure, rapid adoption of hybrid PET/CT systems, and continual product approvals in the cardiac imaging domain.

Market Drivers

Technological Advancements Amplify Diagnostic Precision

The increasing introduction of advanced PET/CT and PET/MRI scanners is a key driver transforming cardiology PET imaging. Major players are heavily investing in AI-enabled imaging systems that offer superior accuracy, faster scan times, and enhanced visualization of myocardial perfusion, coronary flow reserve, and inflammation. These innovations strengthen clinical decision-making and support personalized treatment strategies.

A significant milestone was achieved in June 2024, when Siemens Healthineers launched its PET/CT scanner Biograph Trinion, featuring AI-driven workflows and integrated patient monitoring. Additionally, in September 2024, GE HealthCare received FDA approval for Flyrcado (flurpiridaz F 18), a next-generation PET MPI tracer for diagnosing Coronary Artery Disease (CAD). These advancements highlight the growing adoption of next-level cardiac imaging systems globally.

Market Restraints

High Equipment Costs and Shortage of Skilled Professionals

Despite its diagnostic significance, the market faces limitations due to the high cost of PET/CT systems, which ranges between USD 225,000 and USD 750,000, making these systems difficult to adopt in small and mid-sized healthcare settings.

Furthermore, the shortage of nuclear medicine professionals-including nuclear technologists, radiopharmaceutical specialists, and cardiac imaging physicians-remains a major challenge. Insufficient training opportunities and stringent regulatory requirements slow down widespread adoption, particularly in emerging markets.

Market Opportunities

Growing Demand for Advanced Imaging and Workflow Optimization

The rising global burden of cardiovascular diseases (CVDs) has heightened the demand for early diagnosis and improved treatment planning. This creates strong opportunities for manufacturers offering faster, high-resolution, and workflow-efficient imaging systems.

Partnerships between technology developers and diagnostic providers are accelerating market expansion. For example, IONETIX's partnership with Provision Diagnostic Imaging in February 2024 aims to improve radiotracer availability and reduce diagnostic turnaround times.

Market Challenges

Limited Radiotracer Availability

Radiotracer shortages remain a critical bottleneck for the global market, as many tracers require nearby cyclotron facilities due to their short half-life. In October 2024, the U.K.'s NHS reported severe radioisotope shortages that led to nationwide delays in cardiac imaging procedures. These supply chain fluctuations hinder consistent operations and limit the full utilization of high-value PET equipment.

Segmental Overview

By Source of Payment

The private health insurance/out-of-pocket segment dominated the market in 2024 due to faster approvals, wider provider choice, and personalized treatment packages.

The public segment is expected to witness moderate growth, supported by revised reimbursement proposals from regulatory agencies such as CMS.

By Service Provider

In 2024, hospitals held the largest market share, supported by advanced imaging infrastructure and availability of skilled staff.

Diagnostic centers are projected to grow at the fastest CAGR due to shorter waiting times, cost advantages, and increasing partnerships for PET/CT system procurement.

Regional Insights

North America

North America led the market with USD 1.06 billion in 2024, driven by high CAD prevalence and strong investments in precision diagnostics. The U.S. remains the largest contributor, supported by continual product installations and PET/CT upgrades across hospitals and imaging networks.

Europe

Europe held a substantial market share in 2024, supported by healthcare digitalization initiatives and the presence of leading PET device manufacturers. Investments in diagnostic modernization continue to strengthen regional growth.

Asia Pacific

Asia Pacific is projected to record the highest CAGR during the forecast period due to rising healthcare investments, improved access to advanced imaging, and growing collaborations for radiopharmaceutical development.

Latin America & Middle East/Africa

Both regions are witnessing steady growth driven by increasing CVD incidence, rising healthcare spending, and gradual technology adoption.

Conclusion

With the market expanding from USD 1.91 billion in 2024 to USD 2.56 billion by 2032, the global cardiology PET scan market is poised for consistent growth. Advancements in imaging technologies, expanding diagnostic infrastructure, and rising cardiac disease prevalence will continue to shape the industry's future.

Segmentation By Source of Payment

• Public
• Private Health Insurance/Out-of-pocket

By Service Provider

• Hospitals
• Diagnostic Centers
• Others

By Geography

• North America (By Source of Payment, Service Provider, and Country)
  • U.S.
  • Canada
• Europe (By Source of Payment, Service Provider, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Source of Payment, Service Provider, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Source of Payment, Service Provider, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Source of Payment, Service Provider, and Country/Sub-region)
  • GCC
  • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Recent Industry Developments such as Partnerships, Mergers, and Acquisitions
• 4.2. Prevalence of Cardiac Conditions, Key Countries, 2024
• 4.3. New Product Launches
• 4.4. Key Industry Developments, Key Players

5. Global Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 5.1.1. Public
  • 5.1.2. Private Health Insurance/Out-of-pocket
• 5.2. Market Analysis, Insights and Forecast - By Service Providers
  • 5.2.1. Hospitals
  • 5.2.2. Diagnostic Centers
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 6.1.1. Public
  • 6.1.2. Private Health Insurance/Out-of-pocket
• 6.2. Market Analysis, Insights and Forecast - By Service Providers
  • 6.2.1. Hospitals
  • 6.2.2. Diagnostic Centers
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 7.1.1. Public
  • 7.1.2. Private Health Insurance/Out-of-pocket
• 7.2. Market Analysis, Insights and Forecast - By Service Providers
  • 7.2.1. Hospitals
  • 7.2.2. Diagnostic Centers
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia pacific Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 8.1.1. Public
  • 8.1.2. Private Health Insurance/Out-of-pocket
• 8.2. Market Analysis, Insights and Forecast - By Service Providers
  • 8.2.1. Hospitals
  • 8.2.2. Diagnostic Centers
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 9.1.1. Public
  • 9.1.2. Private Health Insurance/Out-of-pocket
• 9.2. Market Analysis, Insights and Forecast - By Service Providers
  • 9.2.1. Hospitals
  • 9.2.2. Diagnostic Centers
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Cardiology Positron Emission Tomography Scan Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Source of Payment
  • 10.1.1. Public
  • 10.1.2. Private Health Insurance/Out-of-pocket
• 10.2. Market Analysis, Insights and Forecast - By Service Providers
  • 10.2.1. Hospitals
  • 10.2.2. Diagnostic Centers
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. RadNet, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sonic Healthcare Limited
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Akumin Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Apex Radiology
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Alliance Medical Limited
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Novant Health
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. InHealth Group
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Dignity Health
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Concord Medical
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Siemens Healthcare Limited
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Mediworks
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. Other Prominent Players
    • 11.2.12.1. Overview
    • 11.2.12.2. Products
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)